A Study to Evaluate TACE Sequential Tislelizumab as Adjuvant Therapy in Participants With HCC at High Risk of Recurrence After Curative Resection
- Status
- UNKNOWN
- Phase
- PHASE2
Clinical Trials Related to Hepatocellular Carcinoma
Related studies linked through entity extraction aliases.
TT-4 As a Single Agent in Subjects with Advanced Selected Solid Tumors
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2
Efficacy and Safety of TACE in Combination With ICIs for HCC: a Real-world Study
- Status
- COMPLETED
- Phase
- N/A
PD-1 Antibody and Lenvatinib Plus TACE on Downstaging BCLC B/C HCC
- Status
- UNKNOWN
- Phase
- EARLY_PHASE1
The Efficacy of Hepatic Arterial Infusion Chemotherapy (HAIC) Combine Lenvatinib and Durvalumab (HILL) in Advanced Hepatocellular Carcinoma (HCC)
- Status
- UNKNOWN
- Phase
- PHASE2
Fusion Imaging Contrast-enhanced Ultrasound LI-RADS
- Status
- UNKNOWN
- Phase
- NA
TACE Combined with Sintilimab Plus Bevacizumab Biosimilar in Patients with Advanced Hepatocellular Carcinoma (TASK-02)
- Status
- COMPLETED
- Phase
- PHASE2
DYNAmic Immune Microenvironment of HCC Treated With atezolIzumab Plus bevaCizumab
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Intratumor CpG-ODN Injection Boosters Immune Killing Against in Situ Tumor Antigen Release for Advanced Solid Tumors
- Status
- RECRUITING
- Phase
- PHASE1
Adjuvant Therapy With Anlotinib for HCC
- Status
- WITHDRAWN
- Phase
- PHASE2
Deep Liver Phenotyping and Immunology Study
- Status
- RECRUITING
- Phase
- N/A
Hepatic Artery Infusion Chemotherapy (HAIC) Plus Durvalumab for Advanced Hepatocellular Carcinoma
- Status
- COMPLETED
- Phase
- PHASE2
Anti-PD-1/PD-L1 Antibodies Plus Pegylated Interferon Alfa-2b Treatment in Patients With Advanced-Stage HCC
- Status
- UNKNOWN
- Phase
- N/A
Low Dose ICG for Biliary Tract and Tumor Imaging
- Status
- COMPLETED
- Phase
- PHASE2
SHR-1210 Combined With Apatinib Mesylate in the Perioperative Therapy for Hepatocellular Carcinoma
- Status
- UNKNOWN
- Phase
- PHASE2
Toripalimab Plus Sorafenib in Patients With Advanced-Stage Hepatocellular Carcinoma
- Status
- UNKNOWN
- Phase
- PHASE1/PHASE2
Application Value of CEUS Li-RADS in Hepatic Focal Lesions in Patients With Non-high Risk Factors for HCC
- Status
- UNKNOWN
- Phase
- N/A
SBRT and Durvalumab for Inoperable/Unresectable Hepatocellular Carcinoma
- Status
- UNKNOWN
- Phase
- PHASE2
Neoantigen Dendritic Cell Vaccine and Nivolumab in HCC and Liver Metastases From CRC
- Status
- RECRUITING
- Phase
- PHASE2
Study of TACE Combined With Lenvatinib to Prevent Postoperative Recurrence in Patients With MVI Positive HCC
- Status
- UNKNOWN
- Phase
- PHASE1/PHASE2